checkAd

     162  0 Kommentare Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss - Seite 3

    1 B-ENT, 2017, 13, 85-92, Early detection of platinum-induced ototoxicity in adults E. D’heygere, R. Kuhweide, H. Pottel, L. Mus, T. Vauterin, and Bob Lerut.

    2 Company estimates based on publicly available data in the US, Japan, Germany, France, UK, Italy and Spain

    3 Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Petremann M, Tran Van Ba C, Broussy A, Romanet C, Dyhrfjeld-Johnsen J.Otol Neurotol. 2017 Oct;38(9):1355-1361.

     

    Lesen Sie auch

    Seite 3 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss - Seite 3 Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, …